Treatment Information

Back

Prostate Cancer treatment details. Biologic therapy.

BC Cancer Agency, Vancouver, Canada.

Survival: monthsCountry:Canada
Toxiciy Grade:3City/State/Province:Vancouver
Treatments:Biologic therapyHospital:BC Cancer Agency
Drugs:Journal:Link
Date:Apr 2008

Description:

Patients: This phase II study involved 28 men with castration-resistant prostate cancer. All had been treated with hormonal therapy, 18 had been treated with radiation therapy, but none had been treated with chemotherapy. The median age was 67, ranging from 49 to 84 years of age.

Treatment: Patients were treated with the biological therapy sorafenib.

Toxicity: Grade 3 hand-foot syndrome, increased enzyme levels, granulocytopenia, fatigue, lymphopenia, anemia, leukocytopenia, and hypertension were reported. Each was reported in one or two patients. The most common grade 2 toxicities were hand-foot syndrome, fatigue, lymphopenia, and hypoalbuminemia, each occurring in five patients.

Results: The median overall survival was 12.25 months.

Correspondence: Dr. K.N. Chi





Back